Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
8391 Results for "
binding avidity
" in MedChemExpress (MCE) Product Catalog:
Products (8391)
8391 Results for "binding avidity" in MCE Product Catalog:
Cat. No.: HY-N0468R
CAS No.: 63279-13-0
Category:
Cat. No.: HY-P992076
Cat. No.: HY-W020780
CAS No.: 724722-89-8
Synonyms: mPEG5000-Maleimide
Cat. No.: HY-L929
2,527 compounds
In drug discovery and development (R&D) area, target binding and druggability optimization are core processes. Among these attributes, high solubility is critical for a compound to achieve druggability, as it directly impacts the progress of drug R&D. Superior solubility ensures the rapid dissolution and uniform distribution of drug molecules in vivo, thereby enhancing bioavailability and effectively mitigating issues such as suboptimal efficacy, increased dosage requirements, or exacerbated toxic and side effects arising from insufficient solubility.
From the perspective of medicinal chemistry, high-solubility drug fragments serve as high-quality "molecular building blocks". Based on these fragments, lead compounds with potential druggability can be rapidly screened out, which significantly shortens the drug R&D cycle and reduces R&D costs. Meanwhile, the high-solubility drug fragment library can provide diverse options for drug development in different therapeutic areas, offer solutions for the solubility defects of existing clinical drugs, and facilitate the development of novel, highly effective targeted drugs with higher bioavailability and better safety profiles.
MCE has collected and compiled 2,527 experimentally validated small-molecule fragments with high solubility. These fragments can be directly used for drug molecular design, providing high-quality pre-validated solubility fragments that significantly improve the efficiency of lead compound screening and accelerate the progress of drug R&D.
Cat. No.: HY-L924
1,488 compounds
Boronic acid and boronic ester represent a relatively novel and promising chemical structure in drug design. Boronic acid exists in an sp²-hybridized state, possessing an empty p-orbital that can act as a Lewis acid to accept lone pairs from heteroatoms (O, N, or S). This Lewis acidity enables it to form reversible covalent bonds with amino acid residues such as lysine, serine, threonine, and histidine. Currently, five FDA-approved drugs containing boronic acid or boronic ester predominantly involve such covalent binding mechanisms in their interactions with target proteins. Furthermore, boronic acid can serve as a bioisostere for carboxylic acids, phosphates, and phenolic groups, utilized to improve pharmacokinetic properties and enhance drug efficacy.
To date, five boron-containing drugs have been approved by the FDA. The unique properties of boronic acids and boronic esters confer significant potential in drug design, with applications spanning cancer therapy (e.g., multiple myeloma), anti-infectives (e.g., fungal infections, tuberculosis), anti-inflammatory treatments (e.g., atopic dermatitis), antibacterial agents (e.g., carbapenem-resistant bacterial infections), and Reactive Oxygen Species (ROS)-responsive prodrugs, among others. The MCE Boronic Acid/Boronic Ester Fragment Library, which contains 1,488 compounds, serves as a valuable tool for the development of boron-containing drugs.
Cat. No.: HY-L918
317 compounds
Targeted Protein Degradation (TPD) is a novel and promising approach to drug development. It shows great potential for targeting proteins traditionally considered "undruggable" due to the lack of enzymatic function and absence of binding sites by tagging them for degradation or recruiting natural degradation mechanisms.
Molecular glues are a type of small-molecule degraders that primarily induce novel interactions between E3 ubiquitin ligases and target proteins, forming ternary complexes that lead to protein ubiquitination and subsequent proteasomal degradation. Compared with PROTACs, molecular glues generally have lower molecular weights, higher cell permeability, and better drug-like properties. Additionally, the design of molecular glues is relatively simple, without the requirements for complex linkers and ligand optimization. As a result, molecular glues have gradually emerged as a promising therapeutic approach for various diseases.
Multiple types of molecular glues have been reported previously. Analysis of co-crystal complex structures reveals that CRBN-related molecular glues are more versatile. Therefore, MCE researchers select active molecules related to these targets as probes for artificial intelligence (AI) screening.Subsequently, molecular docking technology was used to verify whether the screened molecules retained the key pharmacophore features. Ultimately, we obtained 317 molecular glue analogs, and these compounds serve as powerful tools for the research of molecular glues.
Cat. No.: HY-P75829
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL13RA2; IL-13R Subunit Alpha-2; Interleukin 13 Receptor Subunit Alpha 2; IL-13R-Alpha-2; CD213a2; IL-13RA2; IL-13R; Interleukin-13 Receptor Alpha 2 Variant; IL13BP; Interleukin 13 Receptor Alpha 2 Chain; CT19; Interleukin 13 binding Protein; Interleukin-
Species:
Human
Source:
HEK293
Cat. No.: HY-P75831
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: IL13RA2; IL-13R Subunit Alpha-2; Interleukin 13 Receptor Subunit Alpha 2; IL-13R-Alpha-2; CD213a2; IL-13RA2; IL-13R; Interleukin-13 Receptor Alpha 2 Variant; IL13BP; Interleukin 13 Receptor Alpha 2 Chain; CT19; Interleukin 13 binding Protein; Interleukin-
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P702784
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: OXCT1; SCOT-S; Prev. OXCT; Epididymis Secretory Sperm binding Protein; SCOT; Succinyl-CoA:3-Ketoacid CoA Transferase; Succinyl-CoA:3-Ketoacid Coenzyme A Transferase 1, Mitochondrial; Succinyl CoA:3-Oxoacid CoA Transferase; Somatic-Type Succinyl-CoA:3-Oxoacid CoA-Transferase; Succinyl-CoA:3-Oxoacid CoA Transferase; Succinyl-CoA:3-Ketoacid-CoA Transferase; 3-Oxoacid CoA Transferase 1; 3-Oxoacid CoA Transferase; 3-Oxoacid CoA-Transferase 1; Succinyl-CoA:3-Ketoacid-Coenzyme A Transferase
Species:
Human
Source:
E. coli
Cat. No.: HY-P703974
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: IL13RA2; IL-13R Subunit Alpha-2; Interleukin 13 Receptor Subunit Alpha 2; IL-13R-Alpha-2; CD213a2; IL-13RA2; IL-13R; Interleukin-13 Receptor Alpha 2 Variant; IL13BP; Interleukin 13 Receptor Alpha 2 Chain; CT19; Interleukin 13 binding Protein; Interleukin-
Species:
Human
Source:
HEK293
Cat. No.: HY-P704215
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL13RA2; IL-13R Subunit Alpha-2; Interleukin 13 Receptor Subunit Alpha 2; IL-13R-Alpha-2; CD213a2; IL-13RA2; IL-13R; Interleukin-13 Receptor Alpha 2 Variant; IL13BP; Interleukin 13 Receptor Alpha 2 Chain; CT19; Interleukin 13 binding Protein; Interleukin-
Species:
Human
Source:
HEK293
Cat. No.: HY-P72272
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CBR1; Carbonyl Reductase [NADPH] 1; Prev. CBR; Short Chain Dehydrogenase/Reductase Family 21C, Member 1; SDR21C1; 15-Hydroxyprostaglandin Dehydrogenase [NADP(+)]; Short Chain Dehydrogenase/Reductase Family 21C Member 1; Epididymis Secretory Sperm binding Protein; 20-Beta-Hydroxysteroid Dehydrogenase; 15-Hydroxyprostaglandin Dehydrogenase; NADPH-Dependent Carbonyl Reductase 1; Carbonyl Reductase (NADPH) 1; Alcohol Dehydrogenase [NAD(P)+] CBR1; Carbonyl Reductase (NADPH); Prostaglandin-E(2) 9-Reductase; HCBR1; Prostaglandin 9-Ketoreductase; CRN; Carbonyl Reductase 1; PG-9-KR
Species:
Human
Source:
P. pastoris
Cat. No.: HY-P73024
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EFNA1; GMAN; Prev. TNFAIP4; Tumor Necrosis Factor Alpha-Induced Protein 4; Prev. EPLG1; TNF Alpha-Induced Protein 4; EPH-Related Receptor Tyrosine Kinase Ligand 1; LERK-1; Ephrin-A1; Tumor Necrosis Factor, Alpha-Induced Protein 4; LERK1; Epididymis Secretory Sperm binding Protein; Immediate Early Response Protein B61; Ligand Of Eph-Related Kinase 1; ECKLG; B61; Ephrin A1; Gastric Cancer Metastasis Associated Long Noncoding RNA
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P81195
Synonyms: AMCBX2; CGD; CGD91-phox; CY24B_HUMAN; CYBB; Cytochrome b 245, beta polypeptide; Cytochrome b(558) beta chain; Cytochrome b(558) subunit beta; Cytochrome b-245 heavy chain; Cytochrome b558 subunit beta; GP91 PHOX; gp91-1; gp91-phox; GP91PHOX; Heme-binding membrane glycoprotein gp91phox; NADPH oxidase 2; Neutrophil cytochrome b 91 kDa polypeptide; p22 phagocyte B-cytochrome; P91 PHOX; p91-PHOX; Superoxide-generating NADPH oxidase heavy chain subunit.
Cat. No.: HY-P81282
Synonyms: CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; Ikzf1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.
Cat. No.: HY-P81282A
Synonyms: CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; Ikzf1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.
Cat. No.: HY-P85524
Synonyms: CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros; zinc finger protein; IKAROS; IKAROS family zinc finger 1; Ikaros; Ikaros family zinc finger protein 1; Ikzf1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1; Ikaros; zinc finger protein subfamily 1A 1; Zinc finger protein, subfamily 1A, member 1; ZNFN1A1.
Cat. No.: HY-P85894
Synonyms: C3 binding protein; C3b/C4b receptor; C3BR; C4BR; CD 35; CD35; CD35 antigen; complement component; 3b/4b; receptor 1; Knops blood group; complement component; 3b/4b; receptor 1 including Knops blood group system; Complement component receptor 1; Complement receptor 1; Complement receptor type 1; CR 1; CR1; CR1_HUMAN; KN; Knops blood group antigen
Cat. No.: HY-P86978
Synonyms: C20orf36 antibody; KIAA0835 antibody; KIAA1050 antibody; MTF1 antibody; Myelin transcription factor 1 antibody; Myelin transcription factor I antibody; MYT1 antibody; MYT1_HUMAN antibody; MyTI antibody; PLPB1 antibody; C20orf36 antibody; KIAA0835 antibody; KIAA1050 antibody; MTF1 antibody; Myelin transcription factor 1 antibody; Myelin transcription factor I antibody; MYT1 antibody; MYT1_HUMAN antibody; MyTI antibody; PLPB1 antibody; Proteolipid protein-binding protein antibody;
Cat. No.: HY-P85599
Synonyms: ATP dependent DNA helicase II 80 kDa subunit; ATP dependent DNA helicase II 86 Kd subunit; ATP dependent DNA helicase II; ATP-dependent DNA helicase 2 subunit 2; ATP-dependent DNA helicase II 80 kDa subunit; CTC box binding factor 85 kDa; CTC box-binding factor 85 kDa subunit; CTC85; CTCBF; DNA repair protein XRCC5; Double strand break rejoining; FLJ39089; G22P2; KARP 1; KARP1; Ku 80; Ku autoantigen 80kDa; Ku80; Ku86; Ku86 autoantigen related protein 1; KUB 2; KUB2; Lupus Ku autoantigen protein p86; NFIV; Nuclear factor IV; Thyroid lupus autoantigen; Thyroid-lupus autoantigen; TLAA; X ray repair complementing defective repair in Chinese hamster cells 5; double strand break rejoining; X-ray repair complementing defective repair in Chinese hamster cells 5; double-strand-break rejoining; X-ray repair cross-complementing protein 5; Xray repair complementing defective repair in Chinese hamster cells 5; XRCC 5; XRCC5; XRCC5_HUMAN.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
